Intranasal immunization as a preventive measure against SARS-CoV-2

Abstract

Dear Editor,

It is known that the development of intramuscular RNA vaccination has been an effective preventive measure against SARSCoV-2 infection by producing humoral and cellular immune responses that prevent viremia and systemic manifestations caused by COVID-19. However, Tiboni et al. report that the intramuscular route does not provide complete protection against viral replication due to the absence of activation of the mucosal immunity of the upper airways, preserving the risk of transmission.

Intranasal vaccination is a novel immunization approach that uses the respiratory lining as an entry point for developing antibodies. Intranasal immunization is a promising option to combat COVID-19 since by using the same route of infection as the virus, it sterilizes the respiratory tract and prevents transmission of the virus; moreover, its administration is easy and convenient for people with trypanophobia.